Clinical Trials

Awareness Raising on Clinical Trials

EFCCA routinely shares information from external partners (i.e., industry supporters) aimed at promoting clinical trial awareness.The activities and content below are not affiliated with EFCCA. However, EFCCA invites you to browse through the below sponsored clinical trials that might be of interest to the IBD patient community.

Crohn’s Disease Clinical Study - MK-7240-008

The primary objective of this Crohn’s Disease (CD) Clinical Study is to study the efficacy and safety of Tulisokibart (MK-7240) in participants with moderately to severely active CD. People may qualify to take part in this study if they are 18-75 years old and: Have had CD for at least 3 months and currently have moderate-to-severe active CD Demonstrated inadequate response,...

Ulcerative Colitis Clinical Study - MK-7240-001

The primary objective of this Ulcerative Colitis (UC) Clinical Study is to study the efficacy and safety of Tulisokibart (MK-7240) in adults with moderate-to-severe active UC compared to a placebo.  People may qualify to take part in this study if they are 18-75 years old and: Have had UC for at least 3 months and currently have moderate-to-severe active UC Have at least...

FUZION study

A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease (FUZION CD) Purpose of this study: The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn's disease and to assess the overall safety of guselkumab. Inclusion Criteria: Must have a diagnosis of Crohn's disease with a minimum duration of at least 3...

Boehringer InCharge

IN CHARGE

The InChargeStudy is a clinical research study that will include up to 76 people with Crohn’s disease (CD). The study will look at how safe an investigational medication is and whether it works when taken with a CD medication (ustekinumab) that is already approved for use. The study is sponsored by Boehringer Ingelheim. You can find participating investigative sites at this website: www....

Stenova

STENOVA

Agomab Therapeutics is conducting the STENOVA study, which offers hope to individuals dealing with fibrostenotic Crohn’s disease. The project focuses on AGMB-129, an oral capsule designed to target scar tissue in the intestines, aiming to alleviate symptoms, enhance patients’ quality of life, and potentially reduce the need for surgery.   New Hope for Fibrostenotic Crohn’s Disease...

GLADIATOR

GLADIATOR UC study This study is currently assessing an investigational drug for people with moderately active UC. Recruitment to this study is closed.   Stay tuned for more information!    

CULTIVATE

Do you have Crohn’s disease (CD)? The CULTIVATE team is looking for people with CD to join a clinical research study assessing an investigational drug. Why participate? ✔ Potentially get access to the oral, once-daily, investigational drug at no cost ✔ Be monitored by gastrointestinal (GI) specialists ✔ Feel empowered ✔ Help advance CD research Who can participate? You may be...

OPTIMISE Study

Is there a better way to optimise disease control for patients with ulcerative colitis? A new study aims to find out Achieving and maintaining effective control of ulcerative colitis is the goal of treatment, but, as all patients know, it can be a challenge.  Current management of mild-to-moderate ulcerative colitis is typically guided by symptoms, with therapy increased during a flare and...

Discover the true effect of anaemia in IBD

The new AEGIS-1, and AEGIS-2 studies are aiming to find out whether ST10-021, an oral ferric iron preparation, is safe and effective in the treatment of iron deficiency anaemia (IDA) in non-active ulcerative colitis (UC), and non-active Crohn’s disease (CD). Summary For people with ulcerative colitis (UC) or Crohn’s disease (CD), iron deficiency anaemia (IDA) is a common problem. Symptoms...

TRAFFIC Study

The primary objective of the TRAFFIC clinical research studies is to find out if the investigational medicine being studied is effective in reducing the severity of the symptoms to the point of remission in individuals with moderate to severe ulcerative colitis or Crohn’s disease when compared to placebo. The secondary objective is to evaluate if the investigational medicine being studied is...